Oxford Biomedica Plc has raised a gross £40 million in a private share placement to support its ongoing gene therapy business which includes the manufacture of lentiviral vector for the Novartis product Kymriah. Kymriah was the first chimeric antigen receptor (CAR) T cell therapy to be approved for cancer. Most recently, Oxford Biomedica secured a contract with AstraZeneca Plc to manufacture an adenoviral vector based vaccine for COVID-19.
